These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23433408)

  • 1. Treatment modification of yttrium-90 radioembolization based on quantitative positron emission tomography/CT imaging.
    Chang TT; Bourgeois AC; Balius AM; Pasciak AS
    J Vasc Interv Radiol; 2013 Mar; 24(3):333-7. PubMed ID: 23433408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
    Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
    J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraprocedural yttrium-90 positron emission tomography/CT for treatment optimization of yttrium-90 radioembolization.
    Bourgeois AC; Chang TT; Bradley YC; Acuff SN; Pasciak AS
    J Vasc Interv Radiol; 2014 Feb; 25(2):271-5. PubMed ID: 24461132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma.
    Filippi L; Pelle G; Cianni R; Scopinaro F; Bagni O
    Nucl Med Biol; 2015 Jan; 42(1):59-64. PubMed ID: 25213104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma.
    Mosconi C; Cappelli A; Ascanio S; Pettinari I; Modestino F; Renzulli M; Galaverni MC; Cucchetti A; Gramenzi A; Pettinato C; Golfieri R
    Future Oncol; 2017 Jun; 13(15):1301-1310. PubMed ID: 28343412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F-FDG PET/CT in staging and restaging cholangiocarcinoma].
    Notaristefano A; Niccoli Asabella A; Stabile Ianora AA; Merenda N; Moschetta M; Antonica F; Altini C; Ferrari C; Cesarano E; Rubini G
    Recenti Prog Med; 2013; 104(7-8):328-35. PubMed ID: 24042402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
    Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
    J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
    Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
    J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation exposure during liver surgery after treatment with (90)Y microspheres, evaluated with computer simulations and dosimeter measurements.
    Högberg J; Rizell M; Hultborn R; Svensson J; Henrikson O; Gjertsson P; Bernhardt P
    J Radiol Prot; 2012 Dec; 32(4):439-46. PubMed ID: 23079691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres.
    Depalo T; Traino AC; Bargellini I; Lorenzoni G; Bozzi E; Vivaldi C; Lamastra R; Masi G; Cioni R; Boni G; Volterrani D
    Sci Rep; 2021 Oct; 11(1):19745. PubMed ID: 34611210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study.
    Ibrahim SM; Mulcahy MF; Lewandowski RJ; Sato KT; Ryu RK; Masterson EJ; Newman SB; Benson A; Omary RA; Salem R
    Cancer; 2008 Oct; 113(8):2119-28. PubMed ID: 18759346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Segmental Pneumonitis after Radioembolization.
    Jaureguizar JIB; Sancho L; Páramo M; Rodríguez-Fraile M; Chopitea A; Benito A; Iñarrairaegui M; Sangro B
    J Vasc Interv Radiol; 2018 Sep; 29(9):1305-1306. PubMed ID: 30146206
    [No Abstract]   [Full Text] [Related]  

  • 17. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal Therapy including Yttrium-90 Radioembolization as a Bridging Therapy to Liver Transplantation for a Huge and Locally Advanced Intrahepatic Cholangiocarcinoma.
    Rayar M; Levi Sandri GB; Houssel-Debry P; Camus C; Sulpice L; Boudjema K
    J Gastrointestin Liver Dis; 2016 Sep; 25(3):401-4. PubMed ID: 27689207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated Treatment with
    Filippi L; Di Costanzo GG; Tortora R; Pelle G; Cianni R; Schillaci O; Bagni O
    Cancer Biother Radiopharm; 2019 May; 34(4):231-237. PubMed ID: 30758985
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT.
    Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K
    J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.